NEW YORK, October 27, 2016 /PRNewswire/ --
On Wednesday, October 26, 2016, the NASDAQ Composite ended the trading session at 5,250.27, down 0.63%; the Dow Jones Industrial Average edged 0.17% higher, to finish at 18,199.33; and the S&P 500 closed at 2,139.43, down 0.17%. This morning, Stock-Callers.com reviews the following Biotech stocks: Advaxis Inc. (NASDAQ: ADXS), Cerus Corporation (NASDAQ: CERS), Kite Pharma Inc. (NASDAQ: KITE), and Cerulean Pharma Inc. (NASDAQ: CERU). Learn more about these stocks by accessing their free research reports at:
Princeton, New Jersey-based Advaxis Inc.'s stock fell 1.90%, to finish Wednesday's session at $8.24 with a total volume of 519,980 shares traded. Shares of Advaxis have advanced 0.73% in the past three months. The stock is trading 25.15% and 8.88% below its 50-day and 200-day moving averages, respectively. Shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have a Relative Strength Index (RSI) of 30.74. Free research report on ADXS is available at:
Concord, California headquartered Cerus Corp.'s stock declined 4.02%, to close the day at $5.01. The stock recorded a trading volume of 444,099 shares. Shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have gained 7.74% in the past one year. The Company's shares are trading below its 50-day and 200-day moving averages by 18.15% and 16.23%, respectively. Additionally, the stock has an RSI of 28.86. The complimentary research report on CERS can be downloaded at:
On Wednesday, shares in Santa Monica, California headquartered Kite Pharma Inc. ended the session 0.74% lower at $45.68 with a total volume of 516,166 shares traded. Kite Pharma Inc.'s shares have declined 23.92% in the last one month, 16.21% in the previous three months, and 35.91% in the past one year. The stock is trading 17.92% and 10.39% below its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company, which focuses on the development and commercialization of novel cancer immunotherapy products, have an RSI of 30.98. Visit us today and access our complete research report on KITE at:
On Wednesday, shares in Waltham, Massachusetts-based Cerulean Pharma Inc. recorded a trading volume of 224,016 shares. The stock ended the day 1.71% lower at $0.86. Shares of Cerulean Pharma, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, are trading below its 50-day moving average by 18.61%. Furthermore, shares of the company have an RSI of 45.24. Get free access to your research report on CERU at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA